Bristol Myers Squibb in the news

The article compares Bristol Myers Squibb and Pfizer as investment options for 2026, analyzing their financial performance, risk profiles, and future prospects amidst patent cliffs and regulatory changes.

Bristol Myers Squibb is likely to beat its upcoming earnings estimates, continuing a trend of strong financial performance.

Bristol Myers Squibb announced a successful Phase 3 trial for a Zenbexus combination regimen for multiple myeloma.

Bristol-Myers Squibb shows strong Q2 earnings and raised 2026 sales guidance, with attractive valuation and high dividend yield despite future patent cliffs.

Bristol Myers Squibb and Realty Income are presented as high-yield stock opportunities due to temporary challenges.

Bristol Myers Squibb Co. stock outperformed competitors during a strong trading day.

Bristol-Myers Squibb faces revenue replacement challenges from Eliquis and Opdivo patent expiries, leading to anticipated long-term revenue declines despite short-term growth and increased guidance.

Bristol Myers Squibb received expanded FDA approval for CAMZYOS for pediatric patients with hypertrophic cardiomyopathy, leading to mixed stock performance but a general consensus of undervaluation by analysts.

Bristol Myers Squibb is successfully transitioning its portfolio from older blockbusters to newer drugs, evidenced by strong Q2 2026 growth and an increased 2026 outlook.

Bristol Myers Squibb (BMY) stock appears undervalued based on its Zacks Rank #2 (Buy), Value grade of A, and favorable P/S and P/CF ratios compared to industry averages.

Bristol-Myers Squibb's stock dropped after a downgrade from Leerink Partners.

Bristol Myers Squibb accelerated drug development by deploying Microsoft 365 Copilot across its enterprise, achieving high adoption and significant time savings.

Bristol-Myers Squibb's stock declined after an analyst downgrade highlighted pipeline risks and patent cliff concerns.

Immunome signed Amendment No. 4 to its License Agreement with Bristol-Myers Squibb on October 2, 2026.

Bristol Myers Squibb Co. stock underperformed on Monday compared to its competitors.

Bristol Myers Squibb's EVP, General Counsel Cari Gallman had 4,559 restricted stock units vest, with 2,332 shares withheld for taxes.

Bristol-Myers Squibb's shares fell after Leerink Partners downgraded the pharmaceutical giant due to doubts about its drug development pipeline.

Bristol Myers Squibb launched the 'Time Back' initiative to collect and share patient stories about life after cancer treatment, highlighting the ordinary, cherished moments oncologists rarely see.

Bristol Myers Squibb, Emirates Thalassemia Society, and Dubai Science Park organized the sixth 'Help Save a Life' blood donation drive in Dubai to support patients with chronic blood disorders.

Bristol-Myers Squibb Co shares fell by 3.8% to $58.81 on October 5, 2026, with the stock being considered 3.8% overvalued based on GF Value™, despite strong profitability and a GF Score™ of 72/100, and notable insider selling activity.